Cargando…

Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis

OBJECTIVES: This postmarketing, observational study evaluated the safety and effectiveness of monthly intravenous (IV) ibandronate in Japanese patients with osteoporosis. METHODS: Eligible patients received monthly IV ibandronate 1 mg for 12 months. Adverse drug reactions (ADRs) were evaluated. Chan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Yasuhiro, Hashimoto, Junko, Nishida, Yosuke, Yamagiwa, Chiemi, Tamura, Takashi, Atsumi, Akihide
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Society of Osteoporosis 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362972/ https://www.ncbi.nlm.nih.gov/pubmed/30775537 http://dx.doi.org/10.1016/j.afos.2018.01.001

Ejemplares similares

Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study
por: Takeuchi, Yasuhiro, et al.
Publicado: (2019)

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties
por: Nakai, Kiyohiko, et al.
Publicado: (2014)

Increased Bone Mineral Density with Monthly Intravenous Ibandronate Contributes to Fracture Risk Reduction in Patients with Primary Osteoporosis: Three-Year Analysis of the MOVER Study
por: Hagino, Hiroshi, et al.
Publicado: (2014)

A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis
por: Horikawa, Akira, et al.
Publicado: (2019)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Clinical Efficacy on Fracture Risk and Safety of 0.5 mg or 1 mg/month Intravenous Ibandronate Versus 2.5 mg/day Oral Risedronate in Patients with Primary Osteoporosis
por: Nakamura, Toshitaka, et al.
Publicado: (2013)

Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis
por: Uehara, Masashi, et al.
Publicado: (2021)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Treatment of Polyostotic Fibrous Dysplasia With Intravenous Ibandronate
por: Kazi, Fatima M, et al.
Publicado: (2021)

Efficacy, safety, and compliance of ibandronate treatment for 3 years in postmenopausal Japanese women with primary osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2018)

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis
por: Ma, Zeren, et al.
Publicado: (2016)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis
por: Hou, Yanjie, et al.
Publicado: (2015)

Effects of eldecalcitol and ibandronate on secondary osteoporosis and muscle wasting in rats with adjuvant-induced arthritis
por: Ono, Yuichi, et al.
Publicado: (2018)

Effect of lumbar spinal stenosis on bone mineral density in osteoporosis patients treated with ibandronate
por: Park, Hyung-Youl, et al.
Publicado: (2021)

Efficacy of a Once-Monthly Pill Containing Ibandronate and Cholecalciferol on the Levels of 25-Hydroxyvitamin D and Bone Markers in Postmenopausal Women with Osteoporosis
por: Cho, In-Jin, et al.
Publicado: (2015)

Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis
por: Koike, Takao, et al.
Publicado: (2011)

Postmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2016)

Efficacy and Safety of Monthly 150 mg Oral Ibandronate in Women with Postmenopausal Osteoporosis: A Systematic Review and Meta-analysis of Randomized Controlled Trials
por: Lee, Young Ho, et al.
Publicado: (2011)

Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
por: Lotz, Ethan M., et al.
Publicado: (2019)

Six monthly intravenous zoledronic acid in childhood osteoporosis
por: Munns, CF, et al.
Publicado: (2013)

Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts
por: Zhang, Xiaohui, et al.
Publicado: (2011)

Acute Phase Reactions After Intravenous Infusion of Zoledronic Acid in Japanese Patients with Osteoporosis: Sub-analyses of the Phase III ZONE Study
por: Shiraki, Masataka, et al.
Publicado: (2021)

Comparison of effectiveness and safety of ibandronate and minodronate combined with eldecalcitol in primary osteoporosis of women: A 1-year follow-up study
por: Tanaka, Mizue, et al.
Publicado: (2017)

Presumed congenital nictitating membrane dysplasia in a Japanese white rabbit
por: Masatsugu, Miki, et al.
Publicado: (2022)

Real‐world safety and effectiveness of pembrolizumab in Japanese patients with radically unresectable melanoma: An all‐case postmarketing surveillance in Japan
por: Yamazaki, Naoya, et al.
Publicado: (2022)

Overview of the Premarketing and Postmarketing Requirements for Drugs Granted Japanese Conditional Marketing Approval
por: Matsushita, Shunsuke, et al.
Publicado: (2021)

Safety and effectiveness of apixaban in Japanese patients with nonvalvular atrial fibrillation in clinical practice: A regulatory postmarketing surveillance, the STANDARD study
por: Inoue, Hiroshi, et al.
Publicado: (2019)

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*
por: COOPER, A, et al.
Publicado: (2006)

Comparison of Monthly Ibandronate Versus Weekly Risedronate in Preference, Convenience, and Bone Turnover Markers in Korean Postmenopausal Osteoporotic Women
por: Chung, Yoon-Sok, et al.
Publicado: (2009)

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial
por: Lester, J.E., et al.
Publicado: (2012)

Postmarketing Safety Surveillance and Reevaluation of Danhong Injection: Clinical Study of 30888 Cases
por: Li, Xue-Lin, et al.
Publicado: (2015)

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
por: Devitt, Bianca, et al.
Publicado: (2008)

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
por: Ralston, S. H., et al.
Publicado: (1997)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
por: Derman, Richard, et al.
Publicado: (2009)

Ibandronate: The loading dose concept in the treatment of metastatic bone pain
por: Maier, Gerrit Steffen, et al.
Publicado: (2015)

Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model
por: Chung, Yoon-Sok, et al.
Publicado: (2015)

Safety and Effectiveness of Micafungin in Japanese Pediatric Patients: Results of a Postmarketing Surveillance Study
por: Kobayashi, Chie, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fctkncb1lueksa7su7cv00vcqm